Profiling type I and II interferon responses reveals distinct subgroups of pediatric patients with autoinflammatory disorders.

ABSTRACT:

Background

Elevation of type I interferon (IFN-I) is characteristic of a group of diseases known as type I interferonopathies. Several technologies are available to monitor IFN-I, but there is no consensus on their routine use in medical laboratories.

Objective

We aimed to compare the performance of two technologies for this purpose: NanoString, which monitors messenger RNA expression of interferon-stimulated genes (ISGs), and Simoa, which quantifies IFN-α2 protein in an ultrasensitive way. We also designed a NanoString assay to monitor type II ISGs and tested its value to discriminate clinical conditions.

Methods

A total of 196 samples from patients with diseases associated or not with IFN-I pathway activation were analyzed by NanoString and Simoa.

Results

The

SUBMITTER: Nombel A 

PROVIDER: S-EPMC12002218 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature